Skip to content
C22C22C22

Drawing based on the description in the official product monograph. No photo yet.

“20 mg/12.5 mg: reddish-yellow, circular, film-coated tablets, approximately 8.5 mm in diameter, with "C22" debossed on one side”

C22 pill

Pill with imprint C22 is red & yellow, round, 8.5 mm and has been identified as Hydrochlorothiazide and Olmesartan Medoxomil 12.5 mg / 20 mg. It is used for high blood pressure. It is supplied by Organon Canada Inc.

Sold in Canada

Hydrochlorothiazide and Olmesartan Medoxomil 12.5 mg / 20 mg

Brand
Olmetec Plus
Imprint
C22
Strength
Hydrochlorothiazide 12.5 mg / Olmesartan Medoxomil 20 mg
Used for
High blood pressure
Color
Red, Yellow
Shape
Round
Size
8.5 mm
Form
Tablet
Manufacturer
Organon Canada Inc
Drug class
ARB (blood pressure medicine)
Sold in
Canada
DIN
02319616

Source: Health Canada's Drug Product Database and the official product monograph. Last checked .

Report a mistake

Please do not include personal health information. For questions about your medicine, ask a pharmacist.

All Olmesartan Medoxomil and Hydrochlorothiazide pills and guides

What is Olmesartan Medoxomil and Hydrochlorothiazide used for?

Olmesartan Medoxomil and Hydrochlorothiazide is used for high blood pressure.

Medicine type
ARB (blood pressure medicine); thiazide diuretic (water pill)
Official uses from the US prescribing label

Olmesartan medoxomil and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular (CV) events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with olmesartan medoxomil and hydrochlorothiazide tablets.

Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC).

Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly.

Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal.

Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy.

Olmesartan medoxomil and hydrochlorothiazide tablets may be used alone, or in combination with other antihypertensive drugs.

Limitations of Use Olmesartan medoxomil and hydrochlorothiazide tablets is not indicated for the initial therapy of hypertension.

From the FDA-approved label on DailyMed (published Oct 01, 2026).

Doctors sometimes prescribe a medicine for other reasons too. If you are not sure what yours is for, ask your pharmacist.

Is this your pill? Check every detail

  • Your pill shows C22.
  • It is red & yellow, round, 8.5 mm.
  • Its score line and coating match the details on this page.
  • It came from a pharmacy package that names the same drug.

Sold in Canada as Olmetec Plus by Organon Canada Inc..

In Canada: prescription only.

Ingredients

Active: Hydrochlorothiazide, Olmesartan Medoxomil

Other pills with imprint C 22

Same imprint, different listing. Check the color, size and maker against your pill.

Pills that look similar but are different drugs

Same color and shape, different medicine. This is why the imprint matters.

Other Olmesartan Medoxomil and Hydrochlorothiazide pills